Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%.
One benefited from positive preliminary data from an early-stage clinical trial. Another surged after an unexpected acquisition by a larger company made the news. And the third stock looks to be rebounding from a big sell-off over the past couple of months.
Which stocks made this week's list of the most humongous performers in all of health care? Find out by watching the following slideshow.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
Keith Speights owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.